{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:23:28Z","timestamp":1787354608530,"version":"build-2736575974"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endoscopy"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Background: Low grade dysplasia (LGD) diagnosed on multiple occasions is considered the strongest risk factor for neoplastic progression in patients with Barrett\u2019s esophagus (BE); however, recent studies have shown that aberrant p53 expression may be a more powerful risk factor for progression. This study aimed to compare the association between aberrant p53 expression versus LGD diagnosed on two or more occasions and neoplastic progression risk.<\/jats:p>\n                  <jats:p>Methods: Patients with a BE segment length\u200a\u2265\u200a2\u200acm were included in a multicenter prospective cohort. p53 expression was determined by immunohistochemistry staining. Neoplastic progression was defined as development of high grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Multivariable Cox regression analyses were used to determine the association between selected variables and neoplastic progression risk.<\/jats:p>\n                  <jats:p>Results: 960 patients (median age 62; 73\u200a% men) were included. During a median (interquartile range) follow-up of 6.3 (3.5\u201311.9) years, 81 patients (8\u200a%) developed HGD\/EAC. p53 expression was aberrant in 24\u200a% of patients, and was strongly associated with an increased risk of progression (hazard ratio [HR] 20.0, 95\u200a%CI 10.0\u201340.0). In contrast, LGD on multiple occasions was not similarly associated (HR 0.84, 95\u200a%CI 0.47\u20131.53), after adjustment for age, sex, and segment length. Progression-free survival was better in patients with normal versus aberrant p53 expression, regardless of the histopathological diagnosis (P\u200a&lt;\u200a0.001).<\/jats:p>\n                  <jats:p>Conclusions: Aberrant p53 expression is strongly associated with an increased neoplastic progression risk in BE patients, regardless of the histopathological findings. It may therefore be a better parameter than confirmed LGD on multiple occasions to identify patients who might benefit from ablation therapy.<\/jats:p>","DOI":"10.1055\/a-2863-0566","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:40:36Z","timestamp":1780353636000},"page":"937-946","source":"Crossref","is-referenced-by-count":1,"title":["Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett\u2019s esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study"],"prefix":"10.1055","volume":"58","author":[{"given":"Pauline A.","family":"Zellenrath","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Provoost","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeliena C. M.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"van Gerwen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doukas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jan F.","family":"de Jonge","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun D.","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Honing","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon C. W.","family":"Spaander","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Probar Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The epidemiology of esophageal adenocarcinoma","volume":"154","author":"H G Coleman","year":"2018","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/gutjnl-2014-308802","article-title":"Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression","volume":"65","author":"F Kastelein","year":"2016","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1097\/MEG.0000000000002121","article-title":"Endoscopic management of Barrett's dysplasia and early neoplasia: efficacy, safety and long-term outcomes in a UK tertiary centre","volume":"33","author":"J R White","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1055\/a-2176-2440","article-title":"Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"55","author":"B Weusten","year":"2023","journal-title":"Endoscopy"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.14309\/ajg.0000000000001680","article-title":"Diagnosis and management of Barrett's esophagus: an updated ACG Guideline","volume":"117","author":"N J Shaheen","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1007\/s00464-021-08646-0","article-title":"Improving cost-effectiveness of endoscopic surveillance for Barrett's esophagus by reducing low-value care: a review of economic evaluations","volume":"35","author":"R Vissapragada","year":"2021","journal-title":"Surg Endosc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.gastro.2016.12.008","article-title":"Patients with Barrett's esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to neoplasia","volume":"152","author":"L C Duits","year":"2017","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"doz061","DOI":"10.1093\/dote\/doz061","article-title":"Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort","volume":"33","author":"K Y Song","year":"2020","journal-title":"Dis Esophagus"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/ajg.2010.171","article-title":"Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated","volume":"105","author":"W L Curvers","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/gutjnl-2014-307278","article-title":"Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel","volume":"64","author":"L C Duits","year":"2015","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1365-2559.2007.02706.x","article-title":"Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists","volume":"50","author":"M Kerkhof","year":"2007","journal-title":"Histopathology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2559.2009.03288.x","article-title":"Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry","volume":"54","author":"P V Kaye","year":"2009","journal-title":"Histopathology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1111\/j.1572-0241.2000.03348.x","article-title":"The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression","volume":"95","author":"M Skacel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/j.gastro.2021.10.038","article-title":"Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia","volume":"162","author":"M Redston","year":"2022","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1136\/gutjnl-2012-303594","article-title":"Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus","volume":"62","author":"F Kastelein","year":"2013","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/his.13193","article-title":"p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients","volume":"71","author":"M Younes","year":"2017","journal-title":"Histopathology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10620-019-05586-7","article-title":"Aberrant p53 immunostaining in Barrett's esophagus predicts neoplastic progression: systematic review and meta-analyses","volume":"64","author":"P Snyder","year":"2019","journal-title":"Dig Dis Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.gastro.2018.03.047","article-title":"Detection of mutations in Barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma","volume":"155","author":"M D Stachler","year":"2018","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/00313029800169076","article-title":"Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: an endoscopic study","volume":"30","author":"S Khan","year":"1998","journal-title":"Pathology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1365-2559.2010.03715.x","article-title":"Novel staining pattern of p53 in Barrett's dysplasia--the absent pattern","volume":"57","author":"P V Kaye","year":"2010","journal-title":"Histopathology"},{"key":"ref21","first-page":"93","article-title":"Endoscopic evaluation of gastro-esophageal reflux disease","volume":"72","author":"D Armstrong","year":"1999","journal-title":"Yale J Biol Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/j.1572-0241.2000.02002.x","article-title":"Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus","volume":"95","author":"D S Levine","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/gutjnl-2024-332095","article-title":"p53 mutation biases squamocolumnar junction progenitor cells towards dysplasia rather than metaplasia in Barrett's oesophagus","volume":"74","author":"G Lian","year":"2025","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1038\/s41467-025-63234-3","article-title":"Prevalence of loss-of-function, gain-of-function and dominant-negative mechanisms across genetic disease phenotypes","volume":"16","author":"M Badonyi","year":"2025","journal-title":"Nat Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1038\/s41467-022-31686-6","article-title":"Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure","volume":"13","author":"L Gerasimavicius","year":"2022","journal-title":"Nat Commun"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1053\/j.gastro.2025.09.012","article-title":"AGA Clinical Practice Guideline on surveillance of Barrett's esophagus","volume":"169","author":"S Wani","year":"2025","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/a-2317-8184","article-title":"Stratification of Barrett's esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group","volume":"56","author":"S Menon","year":"2024","journal-title":"Endoscopy"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1053\/j.gastro.2023.07.029","article-title":"The Tissue Systems Pathology Test outperforms pathology review in risk stratifying patients with low-grade dysplasia","volume":"165","author":"A M Khoshiwal","year":"2023","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1470-2045(21)00667-7","article-title":"Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot","volume":"23","author":"N D Pilonis","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2863-0566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:35:34Z","timestamp":1787351734000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2863-0566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":29,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,8,21]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2863-0566","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0013-726X","1438-8812"],"issn-type":[{"value":"0013-726X","type":"print"},{"value":"1438-8812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}